<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clinicoecon Outcomes Res</journal-id><journal-id journal-id-type="iso-abbrev">Clinicoecon Outcomes Res</journal-id><journal-id journal-id-type="publisher-id">Clinicoecon Outcomes Res</journal-id><journal-title-group><journal-title>ClinicoEconomics and Outcomes Research: CEOR</journal-title></journal-title-group><issn pub-type="epub">1178-6981</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28115858</article-id><article-id pub-id-type="pmc">5221484</article-id><article-id pub-id-type="doi">10.2147/CEOR.S122177</article-id><article-id pub-id-type="publisher-id">ceor-9-039</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Grau</surname><given-names>Santiago</given-names></name><xref ref-type="aff" rid="af1-ceor-9-039">1</xref></contrib><contrib contrib-type="author"><name><surname>Azanza</surname><given-names>Jose Ramon</given-names></name><xref ref-type="aff" rid="af2-ceor-9-039">2</xref></contrib><contrib contrib-type="author"><name><surname>Ruiz</surname><given-names>Isabel</given-names></name><xref ref-type="aff" rid="af3-ceor-9-039">3</xref></contrib><contrib contrib-type="author"><name><surname>Vallejo</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="af4-ceor-9-039">4</xref></contrib><contrib contrib-type="author"><name><surname>Mensa</surname><given-names>Josep</given-names></name><xref ref-type="aff" rid="af5-ceor-9-039">5</xref></contrib><contrib contrib-type="author"><name><surname>Maertens</surname><given-names>Johan</given-names></name><xref ref-type="aff" rid="af6-ceor-9-039">6</xref></contrib><contrib contrib-type="author"><name><surname>Heinz</surname><given-names>Werner J</given-names></name><xref ref-type="aff" rid="af7-ceor-9-039">7</xref></contrib><contrib contrib-type="author"><name><surname>Barrueta</surname><given-names>Jon Andoni</given-names></name><xref ref-type="aff" rid="af8-ceor-9-039">8</xref></contrib><contrib contrib-type="author"><name><surname>Peral</surname><given-names>Carmen</given-names></name><xref ref-type="aff" rid="af9-ceor-9-039">9</xref></contrib><contrib contrib-type="author"><name><surname>Mesa</surname><given-names>Francisco Jes&#x000fa;s</given-names></name><xref ref-type="aff" rid="af8-ceor-9-039">8</xref></contrib><contrib contrib-type="author"><name><surname>Barrado</surname><given-names>Miguel</given-names></name><xref ref-type="aff" rid="af10-ceor-9-039">10</xref></contrib><contrib contrib-type="author"><name><surname>Charbonneau</surname><given-names>Claudie</given-names></name><xref ref-type="aff" rid="af11-ceor-9-039">11</xref></contrib><contrib contrib-type="author"><name><surname>Rubio-Rodr&#x000ed;guez</surname><given-names>Dar&#x000ed;o</given-names></name><xref ref-type="aff" rid="af12-ceor-9-039">12</xref><xref ref-type="corresp" rid="c1-ceor-9-039"/></contrib><contrib contrib-type="author"><name><surname>Rubio-Terr&#x000e9;s</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="af12-ceor-9-039">12</xref></contrib></contrib-group><aff id="af1-ceor-9-039"><label>1</label>Pharmacy Department, Hospital del Mar, Universitat Aut&#x000f2;noma de Barcelona, Barcelona</aff><aff id="af2-ceor-9-039"><label>2</label>Clinical Pharmacology Department, Cl&#x000ed;nica Universidad de Navarra, Pamplona</aff><aff id="af3-ceor-9-039"><label>3</label>Infectious Diseases Department, Hospital Universitari Vall d&#x02019;Hebron, Barcelona</aff><aff id="af4-ceor-9-039"><label>4</label>Hematology Department, Hospital Universitario Donostia, San Sebasti&#x000e1;n</aff><aff id="af5-ceor-9-039"><label>5</label>Infectious Diseases Department, Hospital Cl&#x000ed;nic de Barcelona, Barcelona, Spain</aff><aff id="af6-ceor-9-039"><label>6</label>Hematology Department, University Hospital Gasthuisberg, Leuven, Belgium</aff><aff id="af7-ceor-9-039"><label>7</label>Hematology/Oncology Department, Medizinische Klinik und Poliklinik II, Universit&#x000e4;tsklinikum, W&#x000fc;rzburg, Germany</aff><aff id="af8-ceor-9-039"><label>8</label>Medical Department</aff><aff id="af9-ceor-9-039"><label>9</label>Economics and Outcomes Research Department, Pfizer S.L.U, Alcobendas</aff><aff id="af10-ceor-9-039"><label>10</label>Clinical Trials Department, Trial Form Support, Madrid, Spain</aff><aff id="af11-ceor-9-039"><label>11</label>Pharmacoeconomics Department, Pfizer International Operations, Paris, France</aff><aff id="af12-ceor-9-039"><label>12</label>Pharmacoeconomics Department, Health Value, Madrid, Spain</aff><author-notes><corresp id="c1-ceor-9-039">Correspondence: Dar&#x000ed;o Rubio-Rodr&#x000ed;guez, Health Value, C/Virgen de Ar&#x000e1;nzazu, 21. 5&#x000b0; B, Madrid 28034, Spain, Tel/Fax +34 91 729 3503, Email <email>drubiorodriguez@healthvalue.org</email></corresp></author-notes><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2016</year></pub-date><volume>9</volume><fpage>39</fpage><lpage>47</lpage><permissions><copyright-statement>&#x000a9; 2017 Grau et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2017</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#x02013; Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title>Objective</title><p>According to a recent randomized, double-blind clinical trial comparing the combination of voriconazole and anidulafungin (VOR+ANI) with VOR monotherapy for invasive aspergillosis (IA) in patients with hematologic disease or with hematopoietic stem cell transplant, mortality was lower after 6 weeks with VOR+ANI than with VOR monotherapy in a post hoc analysis of patients with galactomannan-based IA. The objective of this study was to compare the cost-effectiveness of VOR+ANI with VOR, from the perspective of hospitals in the Spanish National Health System.</p></sec><sec><title>Methods</title><p>An economic model with deterministic and probabilistic analyses was used to determine costs per life-year gained (LYG) for VOR+ANI versus VOR in patients with galactomannan-based IA. Mortality, adverse event rates, and life expectancy were obtained from clinical trial data. The costs (in 2015 euros [&#x020ac;]) of the drugs and the adverse event-related costs were obtained from Spanish sources. A Tornado plot and a Monte Carlo simulation (1,000 iterations) were used to assess uncertainty of all model variables.</p></sec><sec><title>Results</title><p>According to the deterministic analysis, for each patient treated with VOR+ANI compared with VOR monotherapy, there would be a total of 0.348 LYG (2.529 vs 2.181 years, respectively) at an incremental cost of &#x020ac;5,493 (&#x020ac;17,902 vs &#x020ac;12,409, respectively). Consequently, the additional cost per LYG with VOR+ANI compared with VOR would be &#x020ac;15,785. Deterministic sensitivity analyses confirmed the robustness of these findings. In the probabilistic analysis, the cost per LYG with VOR+ANI was &#x020ac;15,774 (95% confidence interval: &#x020ac;15,763&#x02013;16,692). The probability of VOR+ANI being cost-effective compared with VOR was estimated at 82.5% and 91.9%, based on local cost-effectiveness thresholds of &#x020ac;30,000 and &#x020ac;45,000, respectively.</p></sec><sec><title>Conclusion</title><p>According to the present economic study, combination therapy with VOR+ANI is cost-effective as primary therapy of IA in galactomannan-positive patients in Spain who have hematologic disease or hematopoietic stem cell transplant, compared with VOR monotherapy.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>anidulafungin</kwd><kwd>cost-effectiveness</kwd><kwd>galactomannan</kwd><kwd>invasive aspergillosis</kwd><kwd>voriconazole</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Invasive aspergillosis (IA) is a life-threatening infection, particularly in patients with hematologic disease or who have received hematopoietic stem cell transplantation (HSCT).<xref rid="b1-ceor-9-039" ref-type="bibr">1</xref> Although survival has increased in recent years due to advances in diagnosis and new antifungal drugs,<xref rid="b2-ceor-9-039" ref-type="bibr">2</xref> prognosis of IA continues to be suboptimal, with an attributable mortality of 42%&#x02013;64%.<xref rid="b3-ceor-9-039" ref-type="bibr">3</xref>,<xref rid="b4-ceor-9-039" ref-type="bibr">4</xref> Combination therapies may improve antifungal efficacy but do so at increased cost.</p><p>The public price of treating diagnosis-related group number 580 (systemic infections and parasitic disorders except septicemia with major complications), which includes aspergillosis, has been reported to be &#x020ac;7,173 in Madrid<xref rid="b5-ceor-9-039" ref-type="bibr">5</xref> and &#x020ac;9,072 in Navarra, Spain.<xref rid="b6-ceor-9-039" ref-type="bibr">6</xref> In a German study published in 2014, which looked at Spanish hospital data on the cost of antifungal therapy of IA, voriconazole (VOR) had a lower total treatment cost compared with liposomal amphotericin B (&#x020ac;8,032 and &#x020ac;10,516, respectively).<xref rid="b7-ceor-9-039" ref-type="bibr">7</xref> Given the significant health and economic impact of IA, it is extremely important to select the most appropriate IA therapy strategy.</p><p>Accurate diagnosis of IA is difficult, because the health status of the patient often precludes invasive procedures and biopsy sampling. Given that early diagnosis is fundamental for improving therapeutic outcomes, rapid detection of galactomannan antigen in serum or bronchoalveolar lavage is useful in the early diagnosis and monitoring of IA.<xref rid="b8-ceor-9-039" ref-type="bibr">8</xref></p><p>According to a recent clinical trial in patients with hematologic disease or HSCT, mortality at 6 weeks of IA therapy was lower with a combination of voriconazole and anidulafungin (VOR+ANI) than with VOR monotherapy and was lower in the subgroup of patients receiving combination therapy who had probable IA based on positive galactomannan antigen testing than in the overall population of patients receiving combination therapy.<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref> The objective of our study was to compare the cost-effectiveness of both therapies, from the perspective of hospitals in the Spanish National Health System.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Economic model</title><p>Using an economic model, the efficacy of VOR+ANI combination therapy was compared with VOR monotherapy for the treatment of IA in a hypothetical cohort of 1,000 galactomannan-positive patients. The model consisted of a decision tree (<xref ref-type="fig" rid="f1-ceor-9-039">Figure 1</xref>) predicting outcomes after 6 weeks of therapy. The analysis considered the following variables: mortality or survival rate of the patient; probability of adverse events (AEs) occurring or not; probability of any AEs occurring being serious or mild-to-moderate; costs of antifungal therapy, AE-related costs, and costs of hospital stays (ward and intensive care unit [ICU]); and life expectancy in patients with HSCT who respond satisfactorily to antifungal therapy for IA. Efficacy and toxicity data were obtained from a clinical trial reporting on VOR+ANI combination therapy in 108 patients and VOR monotherapy in 110 patients (NCT00531479).<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref></p><p>The main model inputs are presented in <xref ref-type="table" rid="t1-ceor-9-039">Table 1</xref>. Deterministic and probabilistic analyses were conducted. The base-case deterministic analysis was constructed using mean values for each variable; sensitivity analyses modifying each parameter were also performed for all of the variables presented in <xref ref-type="table" rid="t1-ceor-9-039">Table 1</xref>. Specifically, the sensitivity of the result to variation in the following parameters was assessed (for VOR+ANI or VOR): probability of mortality, duration of hospital stay, life expectancy, drug acquisition cost; probability of occurrence of mild-to-moderate or serious AEs, and costs related to mild-to-moderate or serious AEs. Variation in the duration of antifungal therapy (base-case &#x000b1;7 days) was also considered. Probabilistic analysis was conducted using second-order Monte Carlo simulations<xref rid="b10-ceor-9-039" ref-type="bibr">10</xref> (1,000 iterations), with the objective of assessing the uncertainty of all variables, which is indicated in <xref ref-type="table" rid="t1-ceor-9-039">Table 1</xref>. Monte Carlo simulations use computerized statistical sampling techniques to obtain a probabilistic approximation of the solution of an equation or mathematical model.<xref rid="b11-ceor-9-039" ref-type="bibr">11</xref> The rates were adjusted to beta distributions and the costs to gamma distributions.<xref rid="b10-ceor-9-039" ref-type="bibr">10</xref></p><p>The economic model was applied using the TreeAge Pro 2014 program (TreeAge Software, Inc., Williamstown, MA, USA). All prices and costs in the model were expressed in 2015 euros (&#x020ac;), with the exception of the 7.5% reduction of the price of ANI (Ecalta<sup>&#x000ae;</sup>; Pfizer Inc., NY, USA) in Spain that was authorized in early 2016.</p></sec><sec><title>Mortality</title><p>As shown in <xref ref-type="table" rid="t1-ceor-9-039">Table 1</xref>, according to the clinical trial of Marr et al,<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref> mortality after 6 weeks of IA therapy was significantly lower with VOR+ANI than with VOR monotherapy in galactomannan-positive patients (15.7% and 27.3%, respectively; <italic>p</italic>=0.037).</p></sec><sec><title>Adverse events</title><p>A serious AE was defined as an event for which the patient outcome is death, life-threatening, hospitalization, or permanent disabilities or damage, in accordance with guidance issued by the US Food and Drug Administration.<xref rid="b12-ceor-9-039" ref-type="bibr">12</xref> The overall AE rate in the galactomannan-positive patient group was higher with VOR+ANI (69.7%) than with VOR monotherapy (62.4%); the rate of serious AEs was also higher (19.5% and 14.2%, respectively; <xref ref-type="table" rid="t1-ceor-9-039">Table 1</xref>).<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref></p></sec><sec><title>Drug acquisition costs</title><p>The acquisition costs of VOR (Vfend<sup>&#x000ae;</sup>; Pfizer Inc.) and ANI (Ecalta<sup>&#x000ae;</sup>) were obtained from the official manufacturer&#x02019;s sales prices in Spain, including the recently authorized mandatory discount of 7.5% for ANI (<xref ref-type="table" rid="t2-ceor-9-039">Table 2</xref>).<xref rid="b13-ceor-9-039" ref-type="bibr">13</xref> We also considered the dosage schedules recommended in the Summary of Product Characteristics of both drugs<xref rid="b14-ceor-9-039" ref-type="bibr">14</xref>,<xref rid="b15-ceor-9-039" ref-type="bibr">15</xref> and, in the case of VOR, the average body weight of adults in Spain (70.0 kg; 95% confidence interval [CI]: 67.8&#x02013;76.1 kg), obtained from Ministry of Health databases (<xref ref-type="table" rid="t2-ceor-9-039">Table 2</xref>).<xref rid="b16-ceor-9-039" ref-type="bibr">16</xref> Patients were assumed to receive treatment with ANI (200 mg on day 1, followed by 100 mg every subsequent day of treatment) for at least 2 weeks and no more than 4 weeks.</p></sec><sec><title>AE-related costs</title><p>The costs of serious and mild-to-moderate AEs were calculated from the rates described by Marr et al<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref> and from the unit costs of handling the AE, obtained from Spanish sources (<xref ref-type="table" rid="t1-ceor-9-039">Table 1</xref>).<xref rid="b5-ceor-9-039" ref-type="bibr">5</xref>,<xref rid="b17-ceor-9-039" ref-type="bibr">17</xref>&#x02013;<xref rid="b23-ceor-9-039" ref-type="bibr">23</xref></p></sec><sec><title>Hospitalization costs</title><p>The frequencies of hospitalization (within a timeframe of 6 weeks) with VOR (31.7%) and VOR+ANI (30.4%) on the ward and in the ICU were obtained from data reported by Marr et al;<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref> length of hospital stay for VOR+ANI and VOR alone in the general ward (36.0 and 34.4 days, respectively) and the ICU (14.2 and 13.7 days, respectively) were also taken from this clinical trial. Unit costs of a 1-day stay on the general ward (&#x020ac;457; 95% CI: &#x020ac;366&#x02013;548) and ICU (&#x020ac;1,860; 95% CI: &#x020ac;1,488&#x02013;2,231) were obtained from a previously published Spanish study (<xref ref-type="table" rid="t1-ceor-9-039">Table 1</xref>).<xref rid="b24-ceor-9-039" ref-type="bibr">24</xref></p></sec><sec><title>Life expectancy (time horizon)</title><p>The life expectancy of patients with HSCT who survive after antifungal therapy for IA is ~3 years.<xref rid="b25-ceor-9-039" ref-type="bibr">25</xref>&#x02013;<xref rid="b28-ceor-9-039" ref-type="bibr">28</xref> Therefore, the time horizon (the duration of monitoring of the hypothetical patients of the model) of the presented model was 3.0 years (95% CI: 2.7&#x02013;3.3 years; <xref ref-type="table" rid="t1-ceor-9-039">Table 1</xref>).</p></sec><sec sec-type="results"><title>Presentation of results</title><p>The results are presented as average cost per life-year gained (LYG) by galactomannan-positive patients with IA treated with VOR+ANI and VOR monotherapy and as differences in costs and life-years between the two therapy strategies. Cost per LYG for VOR+ANI compared with VOR monotherapy was calculated. For the probabilistic analysis, cost-effectiveness planes were calculated and probability of cost-effectiveness estimated relative to local willingness-to-pay thresholds of &#x020ac;30,000 and &#x020ac;45,000 as previously reported.<xref rid="b29-ceor-9-039" ref-type="bibr">29</xref>,<xref rid="b30-ceor-9-039" ref-type="bibr">30</xref></p></sec></sec><sec sec-type="results"><title>Results</title><sec sec-type="methods"><title>Deterministic analysis</title><p>In each hypothetical cohort of 1,000 patients receiving either VOR+ANI combination therapy or VOR alone, 157 and 273 deaths were expected to occur, respectively. In surviving patients, 256 and 274 AEs were predicted in patients receiving either VOR+ANI combination therapy or VOR alone, respectively. More serious AEs were expected with VOR+ANI (n=50) than with VOR monotherapy (n=39).</p><p>The median duration of VOR+ANI combination therapy was 14 days (range: 1&#x02013;29 days); the median duration of VOR monotherapy was 42 days (range: 1&#x02013;48 days).<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref> As shown in <xref ref-type="table" rid="t3-ceor-9-039">Table 3</xref>, the average life expectancy per patient was 2.5 years with VOR+ANI and 2.2 years with VOR monotherapy (an increase of 0.348 LYG with VOR+ANI). The average cost per patient of antifungal therapy for IA was &#x020ac;17,902 with VOR+ANI and &#x020ac;12,409 with VOR monotherapy (an additional cost of &#x020ac;5,493 with VOR+ANI). Consequently, the incremental cost per LYG was &#x020ac;15,785 with VOR+ANI versus VOR.</p><p>The results of the univariate sensitivity analyses are represented in the Tornado plot (<xref ref-type="fig" rid="f2-ceor-9-039">Figure 2</xref>). The variables that most influenced the results were mortality probabilities for each of the compared therapy strategies. The variation in the mortality probability with VOR+ANI (0.10&#x02013;0.24) would lead to a cost per LYG with VOR+ANI versus VOR monotherapy from &#x020ac;10,669 to &#x020ac;52,144. The variation in the mortality probability with VOR monotherapy (0.20&#x02013;0.36) would lead to a cost per LYG with combination from &#x020ac;8,924 to &#x020ac;44,509 (<xref ref-type="fig" rid="f2-ceor-9-039">Figure 2</xref>). When the duration of antifungal therapy was varied by &#x000b1;7 days relative to the base-case analysis, the cost per LYG was &#x020ac;9,287 with VOR+ANI versus &#x020ac;22,282 with VOR monotherapy.</p></sec><sec sec-type="methods"><title>Probabilistic analysis</title><p>In the probabilistic analysis, the cost per LYG with VOR+ANI was &#x020ac;15,774 (95% CI: &#x020ac;15,763&#x02013;16,692; <xref ref-type="table" rid="t4-ceor-9-039">Table 4</xref>). The probability that VOR+ANI would be considered cost-effective compared with VOR was estimated at 82.5% and 91.9% at locally established willingness-to-pay thresholds of &#x020ac;30,000 and &#x020ac;45,000, respectively (<xref ref-type="fig" rid="f3-ceor-9-039">Figure 3</xref>). The cost-effectiveness acceptability curves for both therapy options are presented in <xref ref-type="fig" rid="f4-ceor-9-039">Figure 4</xref>.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The pharmacoeconomic model used in this study suggests an increase of 0.348 LYG with VOR+ANI compared with VOR monotherapy for galactomannan test-based IA in each patient with hematologic disease or HSCT. According to the study by Rodriguez-Tudela et al, there were 419 such patients across Spain in 2010.<xref rid="b31-ceor-9-039" ref-type="bibr">31</xref> Therefore, widespread VOR+ANI combination therapy in patients with hematologic disease or HSCT in Spain could provide an annual gain of ~146 years compared with VOR monotherapy. Similarly, our findings suggest that the probability that VOR+ANI combination therapy of IA is cost-effective compared with VOR monotherapy is 82.5% at a previously established local willingness-to-pay threshold of &#x020ac;30,000 per LYG (91.9% at a threshold of &#x020ac;45,000 per LYG).<xref rid="b29-ceor-9-039" ref-type="bibr">29</xref>,<xref rid="b30-ceor-9-039" ref-type="bibr">30</xref></p><p>Certain limitations and inconsistencies of this study must be taken into account when considering these results. This was a theoretical model, which, by definition, was a simulation of real-world clinical practice. Additionally, efficacy and AE data were obtained from an explanatory double-blind, randomized clinical trial (NCT00531479),<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref> as no data from pragmatic clinical trials were available.<xref rid="b32-ceor-9-039" ref-type="bibr">32</xref> Consequently, the results of the economic analysis are applicable only to patients with similar characteristics to those included in that clinical trial. Also, the lower mortality of the subgroup of patients who received VOR+ANI combination therapy for IA indicated by galactomannan testing in the trial reported by Marr et al<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref> was determined by means of a post hoc analysis, with associated methodological limitations.<xref rid="b33-ceor-9-039" ref-type="bibr">33</xref> As noted by Marr et al,<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref> further work is required to confirm the results obtained in the combination therapy subgroup; our economic model was, therefore, also dependent on such limitations. The highest mortality probabilities used in the deterministic sensitivity analyses with VOR+ANI and VOR monotherapy lead to costs per LYG with the combination above &#x020ac;30,000 per LYG.</p><p>Reliability of the presented findings were assessed by Monte Carlo simulation.<xref rid="b34-ceor-9-039" ref-type="bibr">34</xref> In clinicoeconomic research, this statistical approach is used to predict individual clinical outcomes for a hypothetical cohort of patients using theoretical sampling of random variables, the behavior of which is described by means of given sampling distributions.<xref rid="b35-ceor-9-039" ref-type="bibr">35</xref> Therefore, the Monte Carlo simulation shows the effect of the random changes conducted on different parameters and consequently imitates the actual clinical development of the patients. The reliability of the result obtained was effectively confirmed by the sensitivity analyses conducted. According to our probabilistic sensitivity analysis, the probability of VOR+ANI being cost-effective compared with VOR monotherapy was 82.5% versus 91.9%, at local willingness-to-pay thresholds of &#x020ac;30,000 and &#x020ac;45,000 per LYG, respectively.<xref rid="b29-ceor-9-039" ref-type="bibr">29</xref>,<xref rid="b30-ceor-9-039" ref-type="bibr">30</xref> All costs used in the model were taken from Spanish sources, to ensure that the results accurately reflected routine clinical practice in the Spanish healthcare system.</p><p>It was not possible to compare the results and procedures of this study with those from another country, as no similar economic analyses comparing VOR+ANI combination therapy with VOR monotherapy for IA in galactomannan-positive patients were identified. Nor were any studies found that compared the efficacy of other antifungal therapy strategies in IA or in other indications in galactomannan-positive patients. In published studies, only the unit cost of the galactomannan test was assessed, and not its diagnostic role as a possible determinant of the cost-effectiveness of IA therapy.<xref rid="b36-ceor-9-039" ref-type="bibr">36</xref>,<xref rid="b37-ceor-9-039" ref-type="bibr">37</xref> No costs were considered for additional diagnostic tests given as part of a full diagnostic workup or as follow-up to galactomannan antigen testing, under the assumption that these costs would not be substantial.</p></sec><sec><title>Conclusion</title><p>On the basis of the findings of our economic model and probabilistic sensitivity analysis, combination therapy with VOR+ANI may be cost-effective as the primary therapy for IA in galactomannan-positive patients in Spain, compared with VOR monotherapy.</p></sec></body><back><ack><title>Acknowledgments</title><p>Editorial support was provided by Martin Bell, PhD, at Complete Medical Communications, and was funded by Pfizer.</p><p>These results differ slightly from those presented in the poster at the ISPOR Congress, Milan, November 2015, due to a 7.5% reduction of the price of anidulafungin in Spain, which was authorized in early 2016.</p></ack><fn-group><fn><p><bold>Authors contribution</bold></p><p>CRT and DRR developed the economic model. CP, JAB, and FJM reviewed the economic model. All authors had full access to the data, and contributed heavily to the analysis and interpretation of the results. All authors contributed to the drafting of the manuscript and to the subsequent revisions at each stage of the manuscript development. All authors have approved the final version for publication and agreed to remain accountable for the accuracy and integrity of this work. CRT is the guarantor for the overall content of the paper.</p></fn><fn fn-type="COI-statement"><p><bold>Disclosure</bold></p><p>JAB, CP, and FJM are employees of Pfizer S.L.U. (Spain). WJH has received research grants from MSD Sharp &#x00026; Dohme/Merck and Pfizer; served on speaker bureaus for Alexion, Astellas, Basilea, Bristol-Myers Squibb, Chugai Pharma, Gilead, Janssen, MSD Sharp &#x00026; Dohme, and Pfizer; participated in advisory boards for Astellas, Gilead, MSD, and Pfizer; and received travel grants from Alexion, Astellas, MSD Sharp &#x00026; Dohme, Novartis, and Pfizer. CC is an employee of Pfizer Inc. (France). DRR and CRT have received honoraria from Pfizer Inc. in connection with the development of this manuscript. SG, JRA, IR, CV, J Maertens, J Mensa, and MB declare no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-ceor-9-039"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;n-Pe&#x000f1;a</surname><given-names>A</given-names></name><name><surname>Aguilar-Guisado</surname><given-names>M</given-names></name><name><surname>Espigado</surname><given-names>I</given-names></name><name><surname>Cisneros</surname><given-names>JM</given-names></name></person-group><article-title>Antifungal combination therapy for invasive aspergillosis</article-title><source>Clin Infect Dis</source><year>2014</year><volume>59</volume><issue>10</issue><fpage>1437</fpage><lpage>1445</lpage><pub-id pub-id-type="pmid">25048847</pub-id></element-citation></ref><ref id="b2-ceor-9-039"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Upton</surname><given-names>A</given-names></name><name><surname>Kirby</surname><given-names>KA</given-names></name><name><surname>Carpenter</surname><given-names>P</given-names></name><name><surname>Boeckh</surname><given-names>M</given-names></name><name><surname>Marr</surname><given-names>KA</given-names></name></person-group><article-title>Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality</article-title><source>Clin Infect Dis</source><year>2007</year><volume>44</volume><issue>4</issue><fpage>531</fpage><lpage>540</lpage><pub-id pub-id-type="pmid">17243056</pub-id></element-citation></ref><ref id="b3-ceor-9-039"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mihu</surname><given-names>CN</given-names></name><name><surname>Kassis</surname><given-names>C</given-names></name><name><surname>Ramos</surname><given-names>ER</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Hachem</surname><given-names>RY</given-names></name><name><surname>Raad</surname><given-names>II</given-names></name></person-group><article-title>Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?</article-title><source>Cancer</source><year>2010</year><volume>116</volume><issue>22</issue><fpage>5290</fpage><lpage>5296</lpage><pub-id pub-id-type="pmid">20665889</pub-id></element-citation></ref><ref id="b4-ceor-9-039"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagano</surname><given-names>L</given-names></name><name><surname>Caira</surname><given-names>M</given-names></name><name><surname>Candoni</surname><given-names>A</given-names></name><etal/></person-group><article-title>The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study</article-title><source>Haematologica</source><year>2006</year><volume>91</volume><issue>8</issue><fpage>1068</fpage><lpage>1075</lpage><pub-id pub-id-type="pmid">16885047</pub-id></element-citation></ref><ref id="b5-ceor-9-039"><label>5</label><element-citation publication-type="webpage"><source>Servicio Madrile&#x000f1;o de Salud. Order 731/2013</source><comment>[Updated 2013 April 13]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.madrid.org/wleg/servlet/Servidor?opcion=VerHtml&#x00026;nmnorma=8275&#x00026;cdestado=P#_ftn1">http://www.madrid.org/wleg/servlet/Servidor?opcion=VerHtml&#x00026;nmnorma=8275&#x00026;cdestado=P#_ftn1</ext-link></comment><date-in-citation>Accessed July 6, 2016</date-in-citation></element-citation></ref><ref id="b6-ceor-9-039"><label>6</label><element-citation publication-type="webpage"><source>Servicio Navarro de Salud-Osasunbidea. Resolution 626/2014</source><comment>[Updated 2014 June 5]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.boletinesoficiales.com/documentacion/legislacion/documento/RESOLUCION-626-2014-5-junio-Director-Gerente-Servicio-Navarro-Salud-Osasunbidea-actualizan-tarifas-servicios-prestados,50,20140709,10/">http://www.boletinesoficiales.com/documentacion/legislacion/documento/RESOLUCION-626-2014-5-junio-Director-Gerente-Servicio-Navarro-Salud-Osasunbidea-actualizan-tarifas-servicios-prestados,50,20140709,10/</ext-link></comment><date-in-citation>Accessed July 6, 2016</date-in-citation></element-citation></ref><ref id="b7-ceor-9-039"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostermann</surname><given-names>H</given-names></name><name><surname>Solano</surname><given-names>C</given-names></name><name><surname>Jarque</surname><given-names>I</given-names></name><etal/></person-group><article-title>Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain</article-title><source>BMC Pharmacol Toxicol</source><year>2014</year><volume>15</volume><fpage>52</fpage><pub-id pub-id-type="pmid">25253630</pub-id></element-citation></ref><ref id="b8-ceor-9-039"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarque</surname><given-names>I</given-names></name><name><surname>Andreu</surname><given-names>R</given-names></name><name><surname>Salavert</surname><given-names>M</given-names></name><etal/></person-group><article-title>Value of Aspergillus galactomannan antigen detection in the diagnosis and follow-up of invasive aspergillosis in hematological patients</article-title><source>Rev Iberoam Micol</source><year>2003</year><volume>20</volume><issue>3</issue><fpage>116</fpage><lpage>118</lpage><comment>Spanish</comment><pub-id pub-id-type="pmid">15456368</pub-id></element-citation></ref><ref id="b9-ceor-9-039"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marr</surname><given-names>KA</given-names></name><name><surname>Schlamm</surname><given-names>HT</given-names></name><name><surname>Herbrecht</surname><given-names>R</given-names></name><etal/></person-group><article-title>Combination antifungal therapy for invasive aspergillosis: a randomized trial</article-title><source>Ann Intern Med</source><year>2015</year><volume>162</volume><issue>2</issue><fpage>81</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">25599346</pub-id></element-citation></ref><ref id="b10-ceor-9-039"><label>10</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Brigg</surname><given-names>A</given-names></name><name><surname>Sculpher</surname><given-names>M</given-names></name><name><surname>Claxton</surname><given-names>K</given-names></name></person-group><source>Decision Modelling for Health Economic Evaluation</source><publisher-loc>Oxford, UK</publisher-loc><publisher-name>Oxford University Press</publisher-name><year>2006</year></element-citation></ref><ref id="b11-ceor-9-039"><label>11</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>US Environmental Protection Agency</collab></person-group><source>EPA/630/R-97/001 Guiding principles for Monte Carlo analysis</source><comment>[Updated 1997 March 1]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.epa.gov/sites/production/files/2014-11/documents/montecar.pdf">https://www.epa.gov/sites/production/files/2014-11/documents/montecar.pdf</ext-link></comment><date-in-citation>Accessed July 6, 2016</date-in-citation></element-citation></ref><ref id="b12-ceor-9-039"><label>12</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>US Food Drug Administration</collab></person-group><source>What is a serious adverse event?</source><comment>[Updated 2016 January 2]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm">http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm</ext-link></comment><date-in-citation>Accessed January 8, 2016</date-in-citation></element-citation></ref><ref id="b13-ceor-9-039"><label>13</label><element-citation publication-type="webpage"><source>Consejo General de Colegios Oficiales de Farmac&#x000e9;uticos. Bot Plus 2.0</source><comment>[Updated 2016 January 26]. Available from: <ext-link ext-link-type="uri" xlink:href="https://botplusweb.portalfarma.com/">https://botplusweb.portalfarma.com/</ext-link></comment><date-in-citation>Accessed June 25, 2016</date-in-citation></element-citation></ref><ref id="b14-ceor-9-039"><label>14</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group><source>ECALTA summary of product characteristics</source><comment>[Updated 2014 September 10]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.medicines.org.uk/emc/medicine/22690">https://www.medicines.org.uk/emc/medicine/22690</ext-link></comment><date-in-citation>Accessed July 6, 2016</date-in-citation></element-citation></ref><ref id="b15-ceor-9-039"><label>15</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>European Medicines Agency</collab></person-group><source>VFEND summary of product characteristics</source><comment>[Updated 2015 December 24]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.medicines.org.uk/emc/medicine/10059">https://www.medicines.org.uk/emc/medicine/10059</ext-link></comment><date-in-citation>Accessed July 6, 2016</date-in-citation></element-citation></ref><ref id="b16-ceor-9-039"><label>16</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Ministerio de Sanidad Servicios Sociales e Igualdad</collab></person-group><source>Talla y peso medio, seg&#x000fa;n grupo de edad y sexo</source><comment>[Updated 2001 July 13]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.msssi.gob.es/estadEstudios/estadisticas/inforRecopilaciones/atlas/atlasDatos.htm">http://www.msssi.gob.es/estadEstudios/estadisticas/inforRecopilaciones/atlas/atlasDatos.htm</ext-link></comment><date-in-citation>Accessed July 6, 2016</date-in-citation></element-citation></ref><ref id="b17-ceor-9-039"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ojeda</surname><given-names>B</given-names></name><name><surname>de Sande</surname><given-names>LM</given-names></name><name><surname>Casado</surname><given-names>A</given-names></name><name><surname>Merino</surname><given-names>P</given-names></name><name><surname>Casado</surname><given-names>MA</given-names></name></person-group><article-title>Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain</article-title><source>Br J Cancer</source><year>2003</year><volume>89</volume><issue>6</issue><fpage>1002</fpage><lpage>1007</lpage><pub-id pub-id-type="pmid">12966416</pub-id></element-citation></ref><ref id="b18-ceor-9-039"><label>18</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Martin-Iglesias</surname><given-names>S</given-names></name></person-group><source>Estudio de costes y efectividad de la intervenci&#x000f3;n enfermera en el estre&#x000f1;imiento cr&#x000f3;nico</source><comment>[Updated 2006 November 24]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.isciii.es/ISCIII/es/contenidos/fd-el-instituto/fd-organizacion/fd-estructura-directiva/fd-subdireccion-general-servicios-aplicados-formacion-investigacion/fd-centros-unidades/fd-investen-isciii-2/docus/2006_X_encuentro_Investen_Albacete.pdf">http://www.isciii.es/ISCIII/es/contenidos/fd-el-instituto/fd-organizacion/fd-estructura-directiva/fd-subdireccion-general-servicios-aplicados-formacion-investigacion/fd-centros-unidades/fd-investen-isciii-2/docus/2006_X_encuentro_Investen_Albacete.pdf</ext-link></comment><date-in-citation>Accessed July 7, 2016</date-in-citation></element-citation></ref><ref id="b19-ceor-9-039"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llibre-Codina</surname><given-names>JM</given-names></name><name><surname>Casado-G&#x000f3;mez</surname><given-names>MA</given-names></name><name><surname>S&#x000e1;nchez-de la Rosa</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients</article-title><source>Enferm Infecc Microbiol Clin</source><year>2007</year><volume>25</volume><issue>2</issue><fpage>98</fpage><lpage>107</lpage><comment>Spanish</comment><pub-id pub-id-type="pmid">17288907</pub-id></element-citation></ref><ref id="b20-ceor-9-039"><label>20</label><element-citation publication-type="webpage"><source>Presidente de la Gerencia Regional de Salud. Resolution of July 1, 2008</source><comment>[Updated 2008 July 1]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.saludcastil-layleon.es/institucion/es/recopilacion-normativa/asistencia-sanitaria/prestaciones-derechos/resolucion-1-julio-2008-presidente-gerencia-regional-salud-">http://www.saludcastil-layleon.es/institucion/es/recopilacion-normativa/asistencia-sanitaria/prestaciones-derechos/resolucion-1-julio-2008-presidente-gerencia-regional-salud-</ext-link></comment><date-in-citation>Accessed July 6, 2016</date-in-citation></element-citation></ref><ref id="b21-ceor-9-039"><label>21</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Ministerio de Sanidad Servicios Sociales e Igualdad</collab></person-group><source>Norma estatal de los AP GRD V23 por cluster 2009</source><comment>[Updated 2009 November 6]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.msps.es/estadEstudios/estadisticas/docs/NormaGRD2009/NORMA_2009_AP_GRD_V23_CLUSTER.xls">http://www.msps.es/estadEstudios/estadisticas/docs/NormaGRD2009/NORMA_2009_AP_GRD_V23_CLUSTER.xls</ext-link></comment><date-in-citation>Accessed July 6, 2016</date-in-citation></element-citation></ref><ref id="b22-ceor-9-039"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holstenson</surname><given-names>E</given-names></name><name><surname>Ringborg</surname><given-names>A</given-names></name><name><surname>Lindgren</surname><given-names>P</given-names></name><etal/></person-group><article-title>Predictors of costs related to cardiovascular disease among patients with atrial fibrillation in five European countries</article-title><source>Europace</source><year>2011</year><volume>13</volume><issue>1</issue><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">20823043</pub-id></element-citation></ref><ref id="b23-ceor-9-039"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isla</surname><given-names>D</given-names></name><name><surname>Gonz&#x000e1;lez-Rojas</surname><given-names>N</given-names></name><name><surname>Nieves</surname><given-names>D</given-names></name><name><surname>Brosa</surname><given-names>M</given-names></name><name><surname>Finnern</surname><given-names>HW</given-names></name></person-group><article-title>Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel</article-title><source>Clin Transl Oncol</source><year>2011</year><volume>13</volume><issue>7</issue><fpage>460</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">21775273</pub-id></element-citation></ref><ref id="b24-ceor-9-039"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asensio</surname><given-names>A</given-names></name><name><surname>Bouza</surname><given-names>E</given-names></name><name><surname>Grau</surname><given-names>S</given-names></name><name><surname>Rubio-Rodr&#x000ed;guez</surname><given-names>D</given-names></name><name><surname>Rubio-Terr&#x000e9;s</surname><given-names>C</given-names></name></person-group><article-title>Cost of Clostridium difficile associated diarrhea in Spain</article-title><source>Rev Esp Salud Publica</source><year>2013</year><volume>87</volume><issue>1</issue><fpage>25</fpage><lpage>33</lpage><comment>Spanish</comment><pub-id pub-id-type="pmid">23748655</pub-id></element-citation></ref><ref id="b25-ceor-9-039"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>JP</given-names></name><name><surname>Meis</surname><given-names>JF</given-names></name><name><surname>Blijlevens</surname><given-names>NM</given-names></name><name><surname>van&#x02019;t Wout</surname><given-names>JW</given-names></name></person-group><article-title>Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands</article-title><source>Curr Med Res Opin</source><year>2005</year><volume>21</volume><issue>10</issue><fpage>1535</fpage><lpage>1546</lpage><pub-id pub-id-type="pmid">16238893</pub-id></element-citation></ref><ref id="b26-ceor-9-039"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>JP</given-names></name><name><surname>Kern</surname><given-names>WV</given-names></name><name><surname>Cornely</surname><given-names>OA</given-names></name><etal/></person-group><article-title>Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany</article-title><source>Value Health</source><year>2006</year><volume>9</volume><issue>1</issue><fpage>12</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">16441520</pub-id></element-citation></ref><ref id="b27-ceor-9-039"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ament</surname><given-names>AJ</given-names></name><name><surname>H&#x000fc;bben</surname><given-names>MW</given-names></name><name><surname>Verweij</surname><given-names>PE</given-names></name><etal/></person-group><article-title>Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach</article-title><source>J Antimicrob Chemother</source><year>2007</year><volume>60</volume><issue>2</issue><fpage>385</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">17561501</pub-id></element-citation></ref><ref id="b28-ceor-9-039"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>KP</given-names></name><name><surname>Nelson</surname><given-names>AC</given-names></name></person-group><article-title>Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies</article-title><source>Clinicoecon Outcomes Res</source><year>2009</year><volume>2009</volume><issue>1</issue><fpage>35</fpage><lpage>43</lpage></element-citation></ref><ref id="b29-ceor-9-039"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Cock</surname><given-names>E</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Gonz&#x000e1;lez-Juanatey</surname><given-names>JR</given-names></name><name><surname>Azanza-Perea</surname><given-names>JR</given-names></name></person-group><article-title>Threshold value of the cost per year of life gained to recommend the adoption of health technologies in Spain: evidence from a literature review [Valor umbral del coste por a&#x000f1;o de vida ganado para recomendar la adopci&#x000f3;n de tecnolog&#x000ed;as sanitarias en Espa&#x000f1;a: evidencias procedentes de una revisi&#x000f3;n de la literatura]</article-title><source>Pharmacoecon Span Res Artic</source><year>2007</year><volume>4</volume><issue>3</issue><fpage>97</fpage><lpage>107</lpage></element-citation></ref><ref id="b30-ceor-9-039"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacrist&#x000e1;n</surname><given-names>JA</given-names></name><name><surname>Oliva</surname><given-names>J</given-names></name><name><surname>Del Llano</surname><given-names>J</given-names></name><name><surname>Prieto</surname><given-names>L</given-names></name><name><surname>Pinto</surname><given-names>JL</given-names></name></person-group><article-title>What is an efficient health technology in Spain?</article-title><source>Gac Sanit</source><year>2002</year><volume>16</volume><issue>4</issue><fpage>334</fpage><lpage>343</lpage><comment>Spanish</comment><pub-id pub-id-type="pmid">12113733</pub-id></element-citation></ref><ref id="b31-ceor-9-039"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Tudela</surname><given-names>JL</given-names></name><name><surname>Alastruey-Izquierdo</surname><given-names>A</given-names></name><name><surname>Gago</surname><given-names>S</given-names></name><etal/></person-group><article-title>Burden of serious fungal infections in Spain</article-title><source>Clin Microbiol Infect</source><year>2015</year><volume>21</volume><issue>2</issue><fpage>183</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">25658565</pub-id></element-citation></ref><ref id="b32-ceor-9-039"><label>32</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>D</given-names></name><name><surname>Flamant</surname><given-names>R</given-names></name><name><surname>Lellouch</surname><given-names>J</given-names></name></person-group><source>Clinical Trials</source><publisher-loc>London, UK</publisher-loc><publisher-name>Academic Press</publisher-name><year>1980</year></element-citation></ref><ref id="b33-ceor-9-039"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curran-Everett</surname><given-names>D</given-names></name><name><surname>Milgrom</surname><given-names>H</given-names></name></person-group><article-title>Post-hoc data analysis: benefits and limitations</article-title><source>Curr Opin Allergy Clin Immunol</source><year>2013</year><volume>13</volume><issue>3</issue><fpage>223</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">23571411</pub-id></element-citation></ref><ref id="b34-ceor-9-039"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubio-Terr&#x000e9;s</surname><given-names>C</given-names></name><name><surname>Cobo</surname><given-names>E</given-names></name><name><surname>Sacrist&#x000e1;n</surname><given-names>JA</given-names></name><name><surname>Prieto</surname><given-names>L</given-names></name><name><surname>Del Llano</surname><given-names>J</given-names></name><name><surname>Badia</surname><given-names>X</given-names></name></person-group><article-title>Analysis of uncertainty in the economic assessment of health interventions</article-title><source>Med Clin (Barc)</source><year>2004</year><volume>122</volume><issue>17</issue><fpage>668</fpage><lpage>674</lpage><comment>Spanish</comment><pub-id pub-id-type="pmid">15153348</pub-id></element-citation></ref><ref id="b35-ceor-9-039"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paxton</surname><given-names>P</given-names></name><name><surname>Curran</surname><given-names>PJ</given-names></name><name><surname>Bollen</surname><given-names>KA</given-names></name><name><surname>Kirby</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name></person-group><article-title>Monte Carlo experiments: design and implementation</article-title><source>Structural Equation Modeling</source><year>2001</year><volume>8</volume><issue>2</issue><fpage>287</fpage><lpage>312</lpage></element-citation></ref><ref id="b36-ceor-9-039"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;n-Pe&#x000f1;a</surname><given-names>A</given-names></name><name><surname>Gil-Navarro</surname><given-names>MV</given-names></name><name><surname>Aguilar-Guisado</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cost-effectiveness analysis comparing two approaches for empirical antifungal therapy in hematological patients with persistent febrile neutropenia</article-title><source>Antimicrob Agents Chemother</source><year>2013</year><volume>57</volume><issue>10</issue><fpage>4664</fpage><lpage>4672</lpage><pub-id pub-id-type="pmid">23856767</pub-id></element-citation></ref><ref id="b37-ceor-9-039"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Marty</surname><given-names>FM</given-names></name><name><surname>Schwarzinger</surname><given-names>M</given-names></name><name><surname>Koo</surname><given-names>S</given-names></name></person-group><article-title>Meta-analysis and cost comparison of empirical versus pre-emptive antifungal strategies in hematologic malignancy patients with high-risk febrile neutropenia</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>11</issue><fpage>e0140930</fpage><pub-id pub-id-type="pmid">26554923</pub-id></element-citation></ref><ref id="b38-ceor-9-039"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peir&#x000f3;</surname><given-names>S</given-names></name><name><surname>G&#x000f3;mez</surname><given-names>G</given-names></name><name><surname>Rejas</surname><given-names>J</given-names></name><name><surname>Guadarrama</surname><given-names>I</given-names></name><name><surname>Blanca</surname><given-names>AB</given-names></name></person-group><article-title>Length of stay and antifungal treatments costs in patients with systemic mycosis: description and associated factors</article-title><source>Value Health</source><year>2002</year><volume>5</volume><issue>6</issue><fpage>564</fpage></element-citation></ref><ref id="b39-ceor-9-039"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grau Cerrato</surname><given-names>S</given-names></name><name><surname>Mateu-de Antonio</surname><given-names>J</given-names></name><name><surname>Soto Alvarez</surname><given-names>J</given-names></name><etal/></person-group><article-title>Economic evaluation of voriconazole versus amphotericin B in the treatment of invasive aspergilosis</article-title><source>Farm Hosp</source><year>2005</year><volume>29</volume><issue>1</issue><fpage>5</fpage><lpage>10</lpage><comment>Spanish</comment><pub-id pub-id-type="pmid">15773796</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-ceor-9-039" position="float"><label>Figure 1</label><caption><p>Decision tree model.</p><p><bold>Note:</bold> 1- Represents the complementary probability.</p><p><bold>Abbreviations:</bold> AE, adverse event; ANI, anidulafungin; pAEV, probability of AEs occurring with VOR monotherapy; pAEVA, probability of AEs occurring with VOR+ANI combination therapy; pMV, probability of mortality with VOR monotherapy; pMVA, probability of mortality with VOR+ANI combination therapy; pSAEV, probability of serious AEs occurring with VOR monotherapy; pSAEVA, probability of serious AEs occurring with VOR+ANI combination therapy; VOR, voriconazole.</p></caption><graphic xlink:href="ceor-9-039Fig1"/></fig><fig id="f2-ceor-9-039" position="float"><label>Figure 2</label><caption><p>Tornado plot (deterministic sensitivity analysis).</p><p><bold>Abbreviations:</bold> AE, adverse event; ANI, anidulafungin; EV, expected value of incremental cost-effectiveness ratio (&#x020ac;15,784.84 per LYG); LYG, life-year gained; VOR, voriconazole.</p></caption><graphic xlink:href="ceor-9-039Fig2"/></fig><fig id="f3-ceor-9-039" position="float"><label>Figure 3</label><caption><p>Cost-effectiveness plane (Monte Carlo simulation) at: <bold>(A)</bold> a willingness-to-pay threshold of &#x020ac;30,000; and <bold>(B)</bold> a willingness-to-pay threshold of &#x020ac;45,000.</p><p><bold>Abbreviations:</bold> ANI, anidulafungin; LYG, life-year gained; VOR, voriconazole; WTP, willingness-to-pay threshold.</p></caption><graphic xlink:href="ceor-9-039Fig3"/></fig><fig id="f4-ceor-9-039" position="float"><label>Figure 4</label><caption><p>Cost-effectiveness acceptability curve.</p><p><bold>Abbreviations:</bold> ANI, anidulafungin; VOR, voriconazole.</p></caption><graphic xlink:href="ceor-9-039Fig4"/></fig><table-wrap id="t1-ceor-9-039" position="float"><label>Table 1</label><caption><p>Economic model assumptions</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Item</th><th valign="top" align="left" rowspan="1" colspan="1">Average</th><th valign="top" align="left" rowspan="1" colspan="1">Interval<xref ref-type="table-fn" rid="tfn1-ceor-9-039">a</xref></th><th valign="top" align="left" rowspan="1" colspan="1">SD</th><th valign="top" align="left" rowspan="1" colspan="1">Distribution</th><th valign="top" align="left" rowspan="1" colspan="1">Alpha</th><th valign="top" align="left" rowspan="1" colspan="1">Beta</th><th valign="top" align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td colspan="8" valign="top" align="left" rowspan="1"><bold>Mortality rates, %</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VOR+ANI</td><td valign="top" align="left" rowspan="1" colspan="1">15.74</td><td valign="top" align="left" rowspan="1" colspan="1">10.07&#x02013;23.77</td><td valign="top" align="left" rowspan="1" colspan="1">3.50</td><td valign="top" align="left" rowspan="1" colspan="1">Beta</td><td valign="top" align="left" rowspan="1" colspan="1">16.93</td><td valign="top" align="left" rowspan="1" colspan="1">90.62</td><td valign="top" align="left" rowspan="1" colspan="1">Marr et al<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VOR</td><td valign="top" align="left" rowspan="1" colspan="1">27.27</td><td valign="top" align="left" rowspan="1" colspan="1">19.82&#x02013;36.26</td><td valign="top" align="left" rowspan="1" colspan="1">4.19</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">30.51</td><td valign="top" align="left" rowspan="1" colspan="1">81.35</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="8" valign="top" align="left" rowspan="1"><bold>Treatment-related AEs, %</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VOR+ANI</td><td valign="top" align="left" rowspan="1" colspan="1">69.74</td><td valign="top" align="left" rowspan="1" colspan="1">63.49&#x02013;75.33</td><td valign="top" align="left" rowspan="1" colspan="1">3.02</td><td valign="top" align="left" rowspan="1" colspan="1">Beta</td><td valign="top" align="left" rowspan="1" colspan="1">160.49</td><td valign="top" align="left" rowspan="1" colspan="1">69.65</td><td valign="top" align="left" rowspan="1" colspan="1">Marr et al<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VOR</td><td valign="top" align="left" rowspan="1" colspan="1">62.39</td><td valign="top" align="left" rowspan="1" colspan="1">55.92&#x02013;68.45</td><td valign="top" align="left" rowspan="1" colspan="1">3.20</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">142.62</td><td valign="top" align="left" rowspan="1" colspan="1">85.98</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="8" valign="top" align="left" rowspan="1"><bold>Serious treatment-related AEs, %</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VOR+ANI</td><td valign="top" align="left" rowspan="1" colspan="1">19.50</td><td valign="top" align="left" rowspan="1" colspan="1">14.09&#x02013;26.34</td><td valign="top" align="left" rowspan="1" colspan="1">3.13</td><td valign="top" align="left" rowspan="1" colspan="1">Beta</td><td valign="top" align="left" rowspan="1" colspan="1">31.12</td><td valign="top" align="left" rowspan="1" colspan="1">128.48</td><td valign="top" align="left" rowspan="1" colspan="1">Marr et al<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VOR</td><td valign="top" align="left" rowspan="1" colspan="1">14.18</td><td valign="top" align="left" rowspan="1" colspan="1">9.37&#x02013;20.90</td><td valign="top" align="left" rowspan="1" colspan="1">2.94</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">19.85</td><td valign="top" align="left" rowspan="1" colspan="1">120.06</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="8" valign="top" align="left" rowspan="1"><bold>Antifungal treatment cost<xref ref-type="table-fn" rid="tfn2-ceor-9-039">b</xref> &#x020ac;</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VOR+ANI</td><td valign="top" align="left" rowspan="1" colspan="1">10,899.89</td><td valign="top" align="left" rowspan="1" colspan="1">10,817.01&#x02013;11,126.86</td><td valign="top" align="left" rowspan="1" colspan="1">79.04</td><td valign="top" align="left" rowspan="1" colspan="1">Gamma</td><td valign="top" align="left" rowspan="1" colspan="1">19,015.61</td><td valign="top" align="left" rowspan="1" colspan="1">0.57</td><td valign="top" align="left" rowspan="1" colspan="1">Ministerio de Sanidad Servicios Sociales e</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VOR</td><td valign="top" align="left" rowspan="1" colspan="1">6,054.74</td><td valign="top" align="left" rowspan="1" colspan="1">5,971.86&#x02013;6,281.71</td><td valign="top" align="left" rowspan="1" colspan="1">79.04</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">5,867.56</td><td valign="top" align="left" rowspan="1" colspan="1">1.03</td><td valign="top" align="left" rowspan="1" colspan="1">Igualdad;<xref rid="b16-ceor-9-039" ref-type="bibr">16</xref> Consejo General de Colegios Oficiales de Farmac&#x000e9;uticos<xref rid="b13-ceor-9-039" ref-type="bibr">13</xref></td></tr><tr><td colspan="8" valign="top" align="left" rowspan="1"><bold>Mild to moderate AE unit cost<xref ref-type="table-fn" rid="tfn3-ceor-9-039">c</xref> &#x020ac;</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Both</td><td valign="top" align="left" rowspan="1" colspan="1">457.04</td><td valign="top" align="left" rowspan="1" colspan="1">365.64&#x02013;548.45</td><td valign="top" align="left" rowspan="1" colspan="1">46.64</td><td valign="top" align="left" rowspan="1" colspan="1">Gamma</td><td valign="top" align="left" rowspan="1" colspan="1">96.04</td><td valign="top" align="left" rowspan="1" colspan="1">4.76</td><td valign="top" align="left" rowspan="1" colspan="1">Ojeda et al;<xref rid="b17-ceor-9-039" ref-type="bibr">17</xref> Martin-Iglesias;<xref rid="b18-ceor-9-039" ref-type="bibr">18</xref> Llibre-Codina et al;<xref rid="b19-ceor-9-039" ref-type="bibr">19</xref> Presidente de la Gerencia Regional de Salud;<xref rid="b20-ceor-9-039" ref-type="bibr">20</xref> Servicio Madrile&#x000f1;o de Salud;<xref rid="b5-ceor-9-039" ref-type="bibr">5</xref> Marr et al<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref></td></tr><tr><td colspan="8" valign="top" align="left" rowspan="1"><bold>Serious AE unit cost<xref ref-type="table-fn" rid="tfn3-ceor-9-039">c</xref> &#x020ac;</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Both</td><td valign="top" align="left" rowspan="1" colspan="1">1,859.57</td><td valign="top" align="left" rowspan="1" colspan="1">1,487.66&#x02013;2,231.49</td><td valign="top" align="left" rowspan="1" colspan="1">189.75</td><td valign="top" align="left" rowspan="1" colspan="1">Gamma</td><td valign="top" align="left" rowspan="1" colspan="1">96.04</td><td valign="top" align="left" rowspan="1" colspan="1">19.36</td><td valign="top" align="left" rowspan="1" colspan="1">Ojeda et al;<xref rid="b17-ceor-9-039" ref-type="bibr">17</xref> Ministerio de Sanidad Servicios Sociales e Igualdad;<xref rid="b21-ceor-9-039" ref-type="bibr">21</xref> Holstenson et al;<xref rid="b22-ceor-9-039" ref-type="bibr">22</xref> Isla et al;<xref rid="b23-ceor-9-039" ref-type="bibr">23</xref> Servicio Madrile&#x000f1;o de Salud;<xref rid="b5-ceor-9-039" ref-type="bibr">5</xref> Marr et al<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref></td></tr><tr><td colspan="8" valign="top" align="left" rowspan="1"><bold>Hospital stay cost<xref ref-type="table-fn" rid="tfn4-ceor-9-039">d</xref> &#x020ac;</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VOR+ANI</td><td valign="top" align="left" rowspan="1" colspan="1">6,815.59</td><td valign="top" align="left" rowspan="1" colspan="1">5,126.41&#x02013;8,728.69</td><td valign="top" align="left" rowspan="1" colspan="1">918.95</td><td valign="top" align="left" rowspan="1" colspan="1">Gamma</td><td valign="top" align="left" rowspan="1" colspan="1">55.01</td><td valign="top" align="left" rowspan="1" colspan="1">123.90</td><td valign="top" align="left" rowspan="1" colspan="1">Peir&#x000f3; et al;<xref rid="b38-ceor-9-039" ref-type="bibr">38</xref> Asensio et al;<xref rid="b24-ceor-9-039" ref-type="bibr">24</xref> Marr et al<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VOR</td><td valign="top" align="left" rowspan="1" colspan="1">6,274.84</td><td valign="top" align="left" rowspan="1" colspan="1">4,645.32&#x02013;8,127.05</td><td valign="top" align="left" rowspan="1" colspan="1">888.20</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">49.91</td><td valign="top" align="left" rowspan="1" colspan="1">125.72</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td colspan="8" valign="top" align="left" rowspan="1"><bold>Life expectancy<xref ref-type="table-fn" rid="tfn5-ceor-9-039">e</xref> years</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Both</td><td valign="top" align="left" rowspan="1" colspan="1">3.00</td><td valign="top" align="left" rowspan="1" colspan="1">2.70&#x02013;3.30</td><td valign="top" align="left" rowspan="1" colspan="1">0.15</td><td valign="top" align="left" rowspan="1" colspan="1">Gamma</td><td valign="top" align="left" rowspan="1" colspan="1">384.16</td><td valign="top" align="left" rowspan="1" colspan="1">0.01</td><td valign="top" align="left" rowspan="1" colspan="1">Jansen et al;<xref rid="b25-ceor-9-039" ref-type="bibr">25</xref> Jansen et al;<xref rid="b26-ceor-9-039" ref-type="bibr">26</xref> Ament et al;<xref rid="b27-ceor-9-039" ref-type="bibr">27</xref> Krueger and Nelson<xref rid="b28-ceor-9-039" ref-type="bibr">28</xref></td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn1-ceor-9-039"><label>a</label><p>Interval is given as 95% CI unless otherwise indicated;</p></fn><fn id="tfn2-ceor-9-039"><label>b</label><p>body weight in Spanish adults (70.0 kg; 95% CI: 67.76&#x02013;76.13 kg) obtained from Spanish official figures<xref rid="b16-ceor-9-039" ref-type="bibr">16</xref>;</p></fn><fn id="tfn3-ceor-9-039"><label>c</label><p>calculated on the basis of AE with significant cost (NCT00531479);</p></fn><fn id="tfn4-ceor-9-039"><label>d</label><p>calculated from clinical trial data,<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref> 32% of total hospital costs were subtracted as the cost of drugs to avoid double-counting;<xref rid="b38-ceor-9-039" ref-type="bibr">38</xref></p></fn><fn id="tfn5-ceor-9-039"><label>e</label><p>life expectancy of recipients of a hematopoietic stem cell transplant who survive after invasive aspergillosis treatment is ~3 years.<xref rid="b25-ceor-9-039" ref-type="bibr">25</xref>&#x02013;<xref rid="b28-ceor-9-039" ref-type="bibr">28</xref> Interval: &#x000b1;10%.</p></fn><fn id="tfn6-ceor-9-039"><p><bold>Abbreviations:</bold> AE, adverse event; ANI, anidulafungin; CI, confidence interval; SD, standard deviation; VOR, voriconazole.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-ceor-9-039" position="float"><label>Table 2</label><caption><p>Drug acquisition cost calculation</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Body weight<xref ref-type="table-fn" rid="tfn7-ceor-9-039">a</xref> (kg)</th><th valign="top" align="left" rowspan="1" colspan="1">Item</th><th valign="top" align="left" rowspan="1" colspan="1">Day 1</th><th valign="top" align="left" rowspan="1" colspan="1">Days 2&#x02013;7</th><th valign="top" align="left" rowspan="1" colspan="1">Days 2&#x02013;14</th><th valign="top" align="left" rowspan="1" colspan="1">Days 8&#x02013;42</th><th valign="top" align="left" rowspan="1" colspan="1">Total cost (&#x020ac;)</th></tr></thead><tbody><tr><td colspan="7" valign="top" align="left" rowspan="1"><bold>Voriconazole</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">70.0</td><td valign="top" align="left" rowspan="1" colspan="1">Dose (mg/kg)<xref ref-type="table-fn" rid="tfn8-ceor-9-039">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">840</td><td valign="top" align="left" rowspan="1" colspan="1">560</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">600</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Administration<xref ref-type="table-fn" rid="tfn9-ceor-9-039">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">IV</td><td valign="top" align="left" rowspan="1" colspan="1">IV</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Oral</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Cost (&#x020ac;)<xref ref-type="table-fn" rid="tfn10-ceor-9-039">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">517.95</td><td valign="top" align="left" rowspan="1" colspan="1">2,071.79</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">3,465.00</td><td valign="top" align="left" rowspan="1" colspan="1">6,054.74</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">67.8</td><td valign="top" align="left" rowspan="1" colspan="1">Dose (mg/kg)<xref ref-type="table-fn" rid="tfn8-ceor-9-039">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">813</td><td valign="top" align="left" rowspan="1" colspan="1">542</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">600</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Administration<xref ref-type="table-fn" rid="tfn9-ceor-9-039">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">IV</td><td valign="top" align="left" rowspan="1" colspan="1">IV</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Oral</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Cost (&#x020ac;)<xref ref-type="table-fn" rid="tfn10-ceor-9-039">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">501.37</td><td valign="top" align="left" rowspan="1" colspan="1">2,005.48</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">3,465.00</td><td valign="top" align="left" rowspan="1" colspan="1">5,971.86</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">76.1</td><td valign="top" align="left" rowspan="1" colspan="1">Dose (mg/kg)<xref ref-type="table-fn" rid="tfn8-ceor-9-039">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">914</td><td valign="top" align="left" rowspan="1" colspan="1">609</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">600</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Administration<xref ref-type="table-fn" rid="tfn9-ceor-9-039">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">IV</td><td valign="top" align="left" rowspan="1" colspan="1">IV</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Oral</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Cost (&#x020ac;)<xref ref-type="table-fn" rid="tfn10-ceor-9-039">d</xref></td><td valign="top" align="left" rowspan="1" colspan="1">563.34</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">2,253.36</td><td valign="top" align="left" rowspan="1" colspan="1">3,465.00</td><td valign="top" align="left" rowspan="1" colspan="1">6,281.71</td></tr><tr><td colspan="7" valign="top" align="left" rowspan="1"><bold>Anidulafungin</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Any</td><td valign="top" align="left" rowspan="1" colspan="1">Dose (mg)<xref ref-type="table-fn" rid="tfn8-ceor-9-039">b</xref></td><td valign="top" align="left" rowspan="1" colspan="1">200</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">100</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Administration<xref ref-type="table-fn" rid="tfn9-ceor-9-039">c</xref></td><td valign="top" align="left" rowspan="1" colspan="1">IV</td><td valign="top" align="left" rowspan="1" colspan="1">IV</td><td valign="top" align="left" rowspan="1" colspan="1">IV</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Cost (&#x020ac;)</td><td valign="top" align="left" rowspan="1" colspan="1">646.02</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">4,199.13</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">4,845.15</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn7-ceor-9-039"><label>a</label><p>Body weight in Spanish adults (70.0 kg; 95% CI: 67.76&#x02013;76.13 kg) obtained from Spanish official figures<xref rid="b16-ceor-9-039" ref-type="bibr">16</xref>,<xref rid="b39-ceor-9-039" ref-type="bibr">39</xref>;</p></fn><fn id="tfn8-ceor-9-039"><label>b</label><p>doses calculated from Marr et al<xref rid="b9-ceor-9-039" ref-type="bibr">9</xref>;</p></fn><fn id="tfn9-ceor-9-039"><label>c</label><p>obtained from Summary of Product Characteristics<xref rid="b13-ceor-9-039" ref-type="bibr">13</xref>;</p></fn><fn id="tfn10-ceor-9-039"><label>d</label><p>drug acquisition costs were obtained from the approved ex-factory prices in Spain with official 7.5% discount rate as of early 2016.<xref rid="b13-ceor-9-039" ref-type="bibr">13</xref></p></fn><fn id="tfn11-ceor-9-039"><p><bold>Abbreviations:</bold> CI, confidence interval; IV, intravenous.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-ceor-9-039" position="float"><label>Table 3</label><caption><p>Deterministic analysis results: base-case</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Treatment</th><th valign="top" align="left" rowspan="1" colspan="1">Costs (&#x020ac;)</th><th valign="top" align="left" rowspan="1" colspan="1">Cost differences (&#x020ac;)</th><th valign="top" align="left" rowspan="1" colspan="1">Life-years</th><th valign="top" align="left" rowspan="1" colspan="1">LYG</th><th valign="top" align="left" rowspan="1" colspan="1">Cost per LYG<xref ref-type="table-fn" rid="tfn12-ceor-9-039">a</xref> (&#x020ac;)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">VOR+ANI</td><td valign="top" align="left" rowspan="1" colspan="1">17,902</td><td valign="top" align="left" rowspan="1" colspan="1">5,493</td><td valign="top" align="left" rowspan="1" colspan="1">2.529</td><td valign="top" align="left" rowspan="1" colspan="1">0.348</td><td valign="top" align="left" rowspan="1" colspan="1">15,785</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VOR</td><td valign="top" align="left" rowspan="1" colspan="1">12,409</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">2.181</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn12-ceor-9-039"><label>a</label><p>Incremental cost-effectiveness ratio (cost per LYG with VOR+ANI versus VOR monotherapy).</p></fn><fn id="tfn13-ceor-9-039"><p><bold>Abbreviations:</bold> ANI, anidulafungin; LYG, life-year gained; VOR, voriconazole.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-ceor-9-039" position="float"><label>Table 4</label><caption><p>Probabilistic analysis results</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">Cost, &#x020ac; (95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1">LYG (95% CI)</th><th valign="top" align="left" rowspan="1" colspan="1">Cost per LYG<xref ref-type="table-fn" rid="tfn14-ceor-9-039">a</xref> (95% CI)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">VOR+ANI</td><td valign="top" align="left" rowspan="1" colspan="1">18,063 (16,431&#x02013;20,020)</td><td valign="top" align="left" rowspan="1" colspan="1">2.534 (2.224&#x02013;2.843)</td><td valign="top" align="left" rowspan="1" colspan="1">15,774 (15,763&#x02013;16,692)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">VOR</td><td valign="top" align="left" rowspan="1" colspan="1">12,385 (10,720&#x02013;14,206)</td><td valign="top" align="left" rowspan="1" colspan="1">2.174 (1.862&#x02013;2.495)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn14-ceor-9-039"><label>a</label><p>Incremental cost-effectiveness ratio (cost per LYG with VOR+ANI combination therapy vs VOR monotherapy).</p></fn><fn id="tfn15-ceor-9-039"><p><bold>Abbreviations:</bold> ANI, anidulafungin; CI, confidence interval; LYG, life-year gained; VOR, voriconazole.</p></fn></table-wrap-foot></table-wrap></floats-group></article>